Novo Integrated Sciences, Inc. (Novo Integrated), a Nevada corporation, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on July 8, 2024, for the resale of up to 3,500,000 shares of common stock by Streeterville Capital, LLC. The shares are issuable upon conversion of a secured convertible promissory note with a maturity date of April 8, 2025, and a principal sum of $6,210,000. The note was sold in a private placement transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933. Novo Integrated will not receive any proceeds from the sale of the common stock by Streeterville Capital, LLC. The shares may be sold at fixed prices, prevailing market prices, or negotiated transactions, and the registration allows for the shares to be freely tradable upon sale. Novo Integrated is a healthcare company that integrates medical technology and interconnectivity to provide primary care and related wellness products.

Novo Integrated Sciences, Inc. (Novo Integrated), a Nevada corporation, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on July 8, 2024, for the resale of up to 3,500,000 shares of common stock by Streeterville Capital, LLC. The shares are issuable upon conversion of a secured convertible promissory note with a maturity date of April 8, 2025, and a principal sum of $6,210,000. The note was sold in a private placement transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933. Novo Integrated will not receive any proceeds from the sale of the common stock by Streeterville Capital, LLC. The shares may be sold at fixed prices, prevailing market prices, or negotiated transactions, and the registration allows for the shares to be freely tradable upon sale. Novo Integrated is a healthcare company that integrates medical technology and interconnectivity to provide primary care and related wellness products.